For the Inventor, By the Inventor

Enter assignee name

Mechelen, Belgium

Galapagos Nv

USPTO Granted Patents = 116

% Expired Patents = 28.4

CIPO Patents = 5

EPO Patents = 67

Trademarks = 14

Forward Citations = 405

Loading Chart...

Loading Chart...

189 inventors (with patents filed for the assignee):

Christel Jeanne Marie Menet (28 out of 30 patents)

Nicolas Desroy (23 out of 24 patents)

Steven Emiel Van Der Plas (23 out of 23 patents)

4. Philip R Kym (19 out of 59 patents)

5. Xueqing Wang (19 out of 41 patents)

6. Luke Jonathan Alvey (18 out of 19 patents)

7. Reginald Christophe Xavier Brys (18 out of 20 patents)

8. Christophe Peixoto (17 out of 19 patents)

9. Gregory A Gfesser (15 out of 37 patents)

10. Robert J Altenbach (14 out of 46 patents)

11. Andrew Bogdan (13 out of 19 patents)

12. Xavier Marie Bock (12 out of 12 patents)

13. Christopher Gaëtan Housseman (12 out of 12 patents)

14. Bo Liu (12 out of 28 patents)

15. Oscar Mammoliti (12 out of 12 patents)

Core Competencies:

Inflammatory Disorders

Cystic Fibrosis

Polycystic Kidney Disease

ADAMTS Inhibitors

JAK Inhibitors

IL-17C Antibodies

Osteoarthritis Treatment

Degenerative Diseases

Fibrotic Diseases

G Protein-Coupled Receptors

Pharmaceutical Compositions

Molecular Targets

116 patents: Sort by Forward Citations

1. 12472181 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2025-11-18),

2. 12383544 - Methods for the treatment of polycystic kidney disease (2025-08-12),

3. 12264156 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2025-04-01),

4. 12065443 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2024-08-20),

5. 11987621 - Antibodies for IL-17C (2024-05-21),

6. 11975008 - Pharmaceutical compositions comprising a JAK inhibitor (2024-05-07),

7. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

8. 11667633 - Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2023-06-06),

9. 11564923 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2023-01-31),

10. 11345691 - Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2022-05-31),

11. 11339166 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2022-05-24),

12. 11220499 - Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2022-01-11),

13. 11136325 - Pyrrolopyrimidine and pyrrolopyridine derivatives (2021-10-05),

14. 11072611 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2021-07-27),

15. 11000528 - Compound useful for the treatment of degenerative and inflammatory diseases (2021-05-11),

Company Overview

Galapagos NV, headquartered in Mechelen, Belgium, is a biotechnology company focused on developing innovative therapies for various inflammatory disorders and degenerative diseases. The company specializes in pharmaceutical compositions targeting conditions such as cystic fibrosis, polycystic kidney disease, and osteoarthritis. Galapagos is recognized for its research in advanced therapeutic areas, including ADAMTS inhibitors, JAK inhibitors, and IL-17C antibodies, aiming to address unmet medical needs through cutting-edge science.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

116 Patents

#1 in Mechelen

#44 in Belgium

#6,853 in the World

Mechelen, Belgium

Galapagos Nv

Forward Citations = 405

189 inventors:

Christel Jeanne Marie Menet (28 out of 30 patents)

Nicolas Desroy (23 out of 24 patents)

Steven Emiel Van Der Plas (23 out of 23 patents)

4. Philip R Kym (19 out of 59 patents)

5. Xueqing Wang (19 out of 41 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Galapagos Nv. Retrieved from https://idiyas.com/company/galapagos-nv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…